24
Participants
Start Date
April 10, 2023
Primary Completion Date
October 24, 2023
Study Completion Date
April 5, 2024
Hutrukin
Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
Placebo
Placebo control for Hutrukin IV push.
BioBehavioral Research of Austin, A Telemed2U Company, Austin
XBiotech, Inc.
INDUSTRY